ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019
Surgery in reference centers improves survival of sarcoma patients: a nationwide study.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06593899 (The Total Neoadjuvant Therapy for Hypofractionated Radiotherapy Combined with AI Regimens in Soft Tissue Sarcoma of the Extremities), which is not on this map. Cited by 145 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Total Neoadjuvant Therapy for Hypofractionated Radiotherapy Combined with AI Regimens in Soft Tissue Sarcoma of the Extremities: a Phase 2 Single Arm Multicenter Study
Who cites it
145 citing papers in PubMed, 3 syntheses or guidelines pooled it, 316 citations in OpenAlex.
- Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.Cancers · 2025Guideline
- Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.Radiation oncology (London, England) · 2022Pooled it
- Needle tract seeding and abdominal recurrence following pre-treatment biopsy of gastrointestinal stromal tumors (GIST): results of a systematic review.BMC surgery · 2022Pooled it
- Efficacy and Safety of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Uterine Leiomyosarcoma: Results of a Phase 2 Study.Annals of surgical oncology · 2026Trial
- Soft Tissue Reporting and Data System (Soft Tissue-RADS): preliminary validation among fellowship-trained musculoskeletal radiologists.European radiology · 2026Article
- Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3).EClinicalMedicine · 2026Review
- Strategies for Pediatric Diaphyseal Bone Reconstruction of the Lower Limb After Oncologic Resection: A Multicenter Retrospective Analysis.Journal of bone oncology · 2026Article
- Real-World Achievement of Guideline-Concordant Treatment and Survival in Osteosarcoma: A Nationwide Registry Study.Cancer science · 2026Article
- Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe.The oncologist · 2026Article
- Multidisciplinary Surgical Approach to a Locally Advanced Leiomyosarcoma of the Right External Iliac Vein.Annals of surgical oncology · 2026Article
- Networking is Essential for the Proper Management of Rare Cancers: From Recognition to Implementation.Annals of surgical oncology · 2026Article
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
- Diagnosis and Management of Soft-Tissue Sarcomas: Current Insights.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Review
- Molecular profiling and access to treatment for rare cancers in Europe.Nature communications · 2026Article
- Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.EClinicalMedicine · 2026Article
- Article
- Twelve-Month Metastatic State as a Landmark-Based Prognostic Stratifier in Metastatic Sarcoma.Cancers · 2026Article
- Article
- Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.Annals of surgical oncology · 2026Article
- Initial report from the SAR-TRACK (SELNET) registry: a multicentric international retrospective analysis on the quality of the management of limb and trunk wall soft-tissue sarcomas (2012-2022) in Ibero-American countries.Lancet regional health. Americas · 2026Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
54 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB and expert pathological review are mandatory for sarcoma patients nationwide. In the present work, the impact of surgery in a reference center on the survival of sarcoma patients investigated using this national NETSARC registry. PATIENTS AND
methodsPatients' characteristics and follow-up are prospectively collected and data monitored. Descriptive, uni- and multivariate analysis of prognostic factors were conducted in the entire series (N = 35 784) and in the subgroup of incident patient population (N = 29 497).
resultsAmong the 35 784 patients, 155 different histological subtypes were reported. 4310 (11.6%) patients were metastatic at diagnosis. Previous cancer, previous radiotherapy, neurofibromatosis type 1 (NF1), and Li-Fraumeni syndrome were reported in 12.5%, 3.6%, 0.7%, and 0.1% of patients respectively. Among the 29 497 incident patients, 25 851 (87.6%) patients had surgical removal of the sarcoma, including 9949 (33.7%) operated in a NETSARC center. Location, grade, age, size, depth, histotypes, gender, NF1, and surgery outside a NETSARC center all correlated to overall survival (OS), local relapse free survival (LRFS), and event-free survival (EFS) in the incident patient population. NF1 history was one of the strongest adverse prognostic factors for LRFS, EFS, and OS. Presentation to an MDTB was associated with an improved LRFS and EFS, but was an adverse prognostic factor for OS if surgery was not carried out in a reference center. In multivariate analysis, surgery in a NETSARC center was positively correlated with LRFS, EFS, and OS [P < 0.001 for all, with a hazard ratio of 0.681 (95% CI 0.618-0.749) for OS].
conclusionThis nationwide registry of sarcoma patients shows that surgical treatment in a reference center reduces the risk of relapse and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.